Inflection Biosciences recognises the importance of effective strategic partnering at all stages of the drug development process to achieve its business objectives. Partnering is central to the key activities of the company, with research and academic alliance partners providing Inflection Biosciences with access to promising cancer discoveries, contract research organisations underpinning its capital efficient drug development objectives and larger pharmaceutical company partners playing a prominent role in the execution of the later stage clinical development phases followed by launch of products in the market place.
The company secured its pipeline from the Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid. To support the development of AUM302 (formerly IBL-302) the company has collaborated with AUM Biosciences Ltd in Singapore, with AUM Biosciences now responsible for the further development of that program. The IBL-100s program is partnered with Mysthera Therapeutics.
The company has established an international network of research partners to support the development of its programs. The company believes that the research data being achieved through this network will be important in informing its clinical development priorities. Some of the collaboration partnerships which have been announced to date are represented below and include Innoplexus, The University of Texas M. D. Anderson Cancer Center; Thomas Jefferson University, Philadelphia; Munich Klinikum der Universität München, Germany and Lund University Cancer Centre, Sweden.